Is there a place for immunotherapy for tumors with oncogenic driver mutations?
Prof. Dr. T. Berghmans, Institut Jules Bordet, Bruxelles
Dr. F. Aboubakar Nana, Cliniques Universitaires St-Luc, Bruxelles
Dr. M. Brandao, Institut Jules Bordet, Bruxelles
Janssen-Cilag NV 2021. This site is published by Janssen-Cilag NV which is solely responsible for its content. It is intended for Healthcare professionals in Belgium and Luxembourg.